Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1538233

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1538233

Neutralizing Antibody Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Neutralizing Antibody Trends and Forecast

The future of the global neutralizing antibody market looks promising with opportunities in the hospital and clinic, research institute, diagnostic laboratory, and pharmaceutical company markets. The global neutralizing antibody market is expected to grow with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are growing incidence of autoimmune disorders including rheumatoid arthritis, multiple sclerosis, and lupus, rising prevalence of infectious diseases, and increasing awareness of the benefits of antibody-based therapies compared to traditional vaccines and drugs.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Neutralizing Antibody by Segment

The study includes a forecast for the global neutralizing antibody by target virus, antibody type, application, end use, and region.

Neutralizing Antibody Market by Target Virus [Shipment Analysis by Value from 2018 to 2030]:

  • SARS-CoV-2
  • HIV
  • Influenza
  • Ebola
  • Zika
  • Hepatitis C

Neutralizing Antibody Market by Antibody Type [Shipment Analysis by Value from 2018 to 2030]:

  • Monoclonal Antibodies
  • Polyclonal Antibodies

Neutralizing Antibody Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Therapeutics
  • Diagnostics
  • Research and Development
  • Others

Neutralizing Antibody Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical Companies
  • Others

Neutralizing Antibody Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Neutralizing Antibody Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neutralizing antibody companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neutralizing antibody companies profiled in this report include-

  • Regeneron Pharmaceuticals
  • Eli Lilly and Company
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Roche
  • Novartis
  • Merck
  • Pfizer
  • Johnson & Johnson

Neutralizing Antibody Market Insights

Lucintel forecasts that therapeutic will remain the largest segment over the forecast period.

Within this market, pharmaceutical company will remain the largest segment.

North America will remain the largest region over the forecast period due to the existence of important vital firms and a consistent healthcare system across the country.

Features of the Global Neutralizing Antibody Market

Market Size Estimates: Neutralizing antibody market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neutralizing antibody market size by target virus, antibody type, application, end use, and region in terms of value ($B).

Regional Analysis: Neutralizing antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different target virus, antibody type, application, end use, and regions for the neutralizing antibody market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neutralizing antibody market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for neutralizing antibody market?

Answer: The global neutralizing antibody market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the neutralizing antibody market?

Answer: The major drivers for this market are growing incidence of autoimmune disorders including rheumatoid arthritis, multiple sclerosis, and lupus, rising prevalence of infectious diseases, and increasing awareness of the benefits of antibody-based therapies compared to traditional vaccines and drugs.

Q3. What are the major segments for neutralizing antibody market?

Answer: The future of the global neutralizing antibody market looks promising with opportunities in the hospital and clinic, research institute, diagnostic laboratory, and pharmaceutical company markets.

Q4. Who are the key neutralizing antibody market companies?

Answer: Some of the key neutralizing antibody companies are as follows:

  • Regeneron Pharmaceuticals
  • Eli Lilly and Company
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Roche
  • Novartis
  • Merck
  • Pfizer
  • Johnson & Johnson

Q5. Which neutralizing antibody market segment will be the largest in future?

Answer: Lucintel forecasts that therapeutic will remain the largest segment over the forecast period.

Q6. In neutralizing antibody market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the existence of important vital firms and a consistent healthcare system across the country.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the neutralizing antibody market by target virus (SARS-CoV-2, HIV, influenza, Ebola, zika, and hepatitis C), antibody type (monoclonal antibodies and polyclonal antibodies), application (therapeutics, diagnostics, research and development, and others), end use (hospitals and clinics, research institutes, diagnostic laboratories, pharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neutralizing Antibody Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Neutralizing Antibody Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Neutralizing Antibody Market by Target Virus
    • 3.3.1: SARS-CoV-2
    • 3.3.2: HIV
    • 3.3.3: Influenza
    • 3.3.4: Ebola
    • 3.3.5: Zika
    • 3.3.6: Hepatitis C
  • 3.4: Global Neutralizing Antibody Market by Antibody Type
    • 3.4.1: Monoclonal Antibodies
    • 3.4.2: Polyclonal Antibodies
  • 3.5: Global Neutralizing Antibody Market by Application
    • 3.5.1: Therapeutics
    • 3.5.2: Diagnostics
    • 3.5.3: Research and Development
    • 3.5.4: Others
  • 3.6: Global Neutralizing Antibody Market by End Use
    • 3.6.1: Hospitals and Clinics
    • 3.6.2: Research Institutes
    • 3.6.3: Diagnostic Laboratories
    • 3.6.4: Pharmaceutical Companies
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Neutralizing Antibody Market by Region
  • 4.2: North American Neutralizing Antibody Market
    • 4.2.1: North American Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
    • 4.2.2: North American Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
  • 4.3: European Neutralizing Antibody Market
    • 4.3.1: European Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
    • 4.3.2: European Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
  • 4.4: APAC Neutralizing Antibody Market
    • 4.4.1: APAC Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
    • 4.4.2: APAC Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
  • 4.5: ROW Neutralizing Antibody Market
    • 4.5.1: ROW Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
    • 4.5.2: ROW Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Neutralizing Antibody Market by Target Virus
    • 6.1.2: Growth Opportunities for the Global Neutralizing Antibody Market by Antibody Type
    • 6.1.3: Growth Opportunities for the Global Neutralizing Antibody Market by Application
    • 6.1.4: Growth Opportunities for the Global Neutralizing Antibody Market by End Use
    • 6.1.5: Growth Opportunities for the Global Neutralizing Antibody Market by Region
  • 6.2: Emerging Trends in the Global Neutralizing Antibody Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Neutralizing Antibody Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neutralizing Antibody Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Regeneron Pharmaceuticals
  • 7.2: Eli Lilly and Company
  • 7.3: AstraZeneca
  • 7.4: GlaxoSmithKline
  • 7.5: Sanofi
  • 7.6: Roche
  • 7.7: Novartis
  • 7.8: Merck
  • 7.9: Pfizer
  • 7.10: Johnson & Johnson
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!